Related Experiment Video
Updated: Aug 17, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Menopausal hormone therapy after breast cancer
1Harvard Medical School, Boston, Massachusetts, USA. graham.colditz@channing.harvard.edu
Abstract:
The use of postmenopausal hormone therapy after breast cancer remains controversial. Evidence shows variation by study design, and even among three randomized controlled trials there is substantial heterogeneity of results. Two Swedish trials of comparable size show relative risks of recurrence of 3.3 and 0.82 on comparing women receiving postmenopausal hormone therapy with control women. The extent of use of tamoxifen and concomitant use of progestins in combination with estrogen, although raised as one possible explanation for this heterogeneity, are not supported by evidence from trials of high-dose progestins used after breast cancer. Caution is needed when considering the use of postmenopausal hormone therapy after breast cancer.
Related Concept Videos
Menopause
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Disorders of the Female Reproductive System
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...